Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Aradigm Corporation    ARDM

ARADIGM CORPORATION (ARDM)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/09/2018 10/10/2018 10/11/2018 10/12/2018 10/15/2018 Date
1.38(c) 1.3(c) 1.25(c) 1.38(c) 1.31 Last
26 365 42 877 21 846 147 547 33 768 Volume
-1.42% -5.80% -3.85% +10.40% -5.07% Change
More quotes
Financials (USD)
More Financials
Company
Aradigm Corp. operates as a pharmaceutical company, which focuses on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases by pulmonologists.Its technologies include diabetes and pain management, AERx essence... 
More about the company
Latest news on ARADIGM CORPORATION
09/17ARADIGM CORP : Creation of a Direct Financial Obligation or an Obligation under ..
AQ
09/10ARADIGM CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rul..
AQ
08/16ARADIGM CORP : Creation of a Direct Financial Obligation or an Obligation under ..
AQ
08/14ARADIGM : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
08/14ARADIGM CORP : Results of Operations and Financial Condition (form 8-K)
AQ
08/14ARADIGM : Announces Second Quarter 2018 Financial Results
PU
08/14ARADIGM : 2Q Earnings Snapshot
AQ
07/17ARADIGM CORP : Creation of a Direct Financial Obligation or an Obligation under ..
AQ
07/10ARADIGM : Announces the Appointment of Dr. Theresa Matkovits to the Board of Dir..
AQ
07/06ARADIGM CORP : Material Modification to Rights of Security Holders, Change in Di..
AQ
More news
Sector news : Bio Therapeutic Drugs
10/11GILEAD SCIENCES : Allogene's Upsized IPO Prices at High End of Range
DJ
10/05ABBVIE : Receives Health Canada Approval of Orilissa for Endometriosis Pain Trea..
DJ
10/04J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion
RE
10/02GILEAD SCIENCES : Allogene Sets IPO at 16 Million Shares; Sees Pricing $16-$18
DJ
09/28FDA Approves Libtayo to Treat Advanced Cutaneous Squamous Cell Carcinoma
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
12:44aAradigm Co. $ARDM Receives Average Recommendation of “Hold” from Brokerages  
10/10Aradigm Co. $ARDM Receives Consensus Recommendation of “Hold” from Analysts  
10/06Aradigm $ARDM vs. CONMED $CNMD Head to Head Contrast  
10/03Top 8 Performing Breakout Stocks within the last Week  
10/03UPSIDE MOMENTUM ALERT: $ARDM ARADIGM CORP COMMON STOCK ? TradeIdeas via  
More tweets
Qtime:13
News from SeekingAlpha
10/03Midday Gainers / Losers (10/03/2018) 
10/03HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (10/03/2018) 
10/03Aradigm up 56% 
08/14Aradigm misses by $0.03, beats on revenue 
06/21Midday Gainers / Losers (06/21/2018) 
Chart ARADIGM CORPORATION
Duration : Period :
Aradigm Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARADIGM CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Average target price -
Spread / Average Target -100%
EPS Revisions
Managers
NameTitle
John M. Siebert Executive Chairman, Chief Executive Officer & CFO
Virgil D. Thompson Independent Director
Frederick M. Hudson Director
Edwin H. Gordon Director
Theresa Matkovits Director
Sector and Competitors
1st jan.Capitalization (M$)
ARADIGM CORPORATION-79.40%19
GILEAD SCIENCES2.72%93 985
VERTEX PHARMACEUTICALS20.99%44 892
REGENERON PHARMACEUTICALS2.18%39 451
NEUROCRINE BIOSCIENCES, INC.43.68%9 776
GENMAB-10.38%8 786